Drugs / iPSC-derived RPE
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT05445063 | Aug 2022 → Jul 2026 overdue | macular degeneration | Beijing Tongren Hospital | Recruiting | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT04339764 | Sep 2020 → May 2029 expected | diffuse secondary choroid atrophy, dry age related macular degeneration | National Eye Institute (NEI) | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | iPSC-derived RPE | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04339764 ↗ |
| Modality | Cell therapy | “potential autologous cell-based therapy for GA associated with AMD” NCT04339764 ↗ |
| Route | Other | “subretinal transplantation of autologous iPSC-derived RPE” NCT04339764 ↗ |